8-K filed October 12, 2022, 7:59 PM ET ticker TARS CIK 0001819790

leadership confidence high sentiment neutral materiality 0.60

Tarsus expands board to nine, appoints Scott Morrison, plans Chairperson transition

Tarsus Pharmaceuticals, Inc.

Scott Morrison appointed to Board as Class III director effective Oct 6, 2022, and as Audit Committee Chair.
Board expanded from eight to nine directors; new Commercial Committee formed with Morrison, Yarno, Yeu-Lin, Crane (Chair).
Michael Ackermann expected to transition off Board by end of 2022; Bobak Azamian to become Chairperson, Wendy Yarno Lead Independent Director.
Morrison receives initial equity grant: option for 14,000 shares plus 4,000 RSUs.
Morrison is independent under Nasdaq standards and qualifies as audit committee financial expert.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Scott Morrison

Director

TARS · Tarsus Pharmaceuticals, Inc.

Effective: 2022-10-06
Filed: October 12, 2022, 7:59 PM ET

expanded the size of the Board from eight to nine directors and appointed Scott Morrison to the Board, effective immediately.

Role change

Bobak Azamian

Chairperson of the Board

TARS · Tarsus Pharmaceuticals, Inc.

Filed: October 12, 2022, 7:59 PM ET

Bobak Azamian, the Company’s Chief Executive Officer and current member of the Board will be appointed as Chairperson of the Board

Role change

Wendy Yarno

Lead Independent Director

TARS · Tarsus Pharmaceuticals, Inc.

Filed: October 12, 2022, 7:59 PM ET

Wendy Yarno, current member of the Board, will be appointed as Lead Independent Director

Departed

Michael Ackermann

Chairperson of the Board

TARS · Tarsus Pharmaceuticals, Inc.

Successor: Bobak Azamian
Filed: October 12, 2022, 7:59 PM ET

Michael Ackermann, the Chairperson of the Board, expected to transition off the Board by the end of the 2022 calendar year

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Scott Morrison was appointed as Director at Tarsus Pharmaceuticals, Inc..

Action: appointed
Role: Director

Exact text from the filing

expanded the size of the Board from eight to nine directors and appointed Scott Morrison to the Board, effective immediately.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.9

Bobak Azamian was appointed as Chairperson of the Board at Tarsus Pharmaceuticals, Inc..

Action: will be appointed
Role: Chairperson of the Board

Exact text from the filing

Bobak Azamian, the Company’s Chief Executive Officer and current member of the Board will be appointed as Chairperson of the Board

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.9

Wendy Yarno was appointed as Lead Independent Director at Tarsus Pharmaceuticals, Inc..

Action: will be appointed
Role: Lead Independent Director

Exact text from the filing

Wendy Yarno, current member of the Board, will be appointed as Lead Independent Director

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.9

Michael Ackermann changed role as Chairperson of the Board at Tarsus Pharmaceuticals, Inc..

Action: expected to transition off
Role: Chairperson of the Board

Exact text from the filing

Michael Ackermann, the Chairperson of the Board, expected to transition off the Board by the end of the 2022 calendar year

View on SEC.gov

Tarsus Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001819790-22-000033

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.